Jílková Adéla, Rubešová Petra, Fanfrlík Jindřich, Fajtová Pavla, Řezáčová Pavlína, Brynda Jiří, Lepšík Martin, Mertlíková-Kaiserová Helena, Emal Cory D, Renslo Adam R, Roush William R, Horn Martin, Caffrey Conor R, Mareš Michael
Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 16610 Prague, Czech Republic.
Eastern Michigan University, 541 Mark Jefferson, Ypsilanti, Michigan 48197, United States.
ACS Infect Dis. 2021 May 14;7(5):1077-1088. doi: 10.1021/acsinfecdis.0c00501. Epub 2020 Nov 11.
Schistosomiasis, a parasitic disease caused by blood flukes of the genus , is a global health problem with over 200 million people infected. Treatment relies on just one drug, and new chemotherapies are needed. cathepsin B1 (SmCB1) is a critical peptidase for the digestion of host blood proteins and a validated drug target. We screened a library of peptidomimetic vinyl sulfones against SmCB1 and identified the most potent SmCB1 inhibitors reported to date that are active in the subnanomolar range with second order rate constants () of ∼2 × 10 M s. High resolution crystal structures of the two best inhibitors in complex with SmCB1 were determined. Quantum chemical calculations of their respective binding modes identified critical hot spot interactions in the S1' and S2 subsites. The most potent inhibitor targets the S1' subsite with an -hydroxysulfonic amide moiety and displays favorable functional properties, including bioactivity against the pathogen, selectivity for SmCB1 over human cathepsin B, and reasonable metabolic stability. Our results provide structural insights for the rational design of next-generation SmCB1 inhibitors as potential drugs to treat schistosomiasis.
血吸虫病是由血吸虫属的血吸虫引起的一种寄生虫病,是一个全球健康问题,有超过2亿人受到感染。治疗仅依赖一种药物,因此需要新的化疗方法。组织蛋白酶B1(SmCB1)是消化宿主血液蛋白的关键肽酶,也是一个经过验证的药物靶点。我们针对SmCB1筛选了一个拟肽乙烯砜文库,并鉴定出了迄今为止报道的最有效的SmCB1抑制剂,它们在亚纳摩尔范围内具有活性,二级速率常数()约为2×10 M s。确定了两种最佳抑制剂与SmCB1复合物的高分辨率晶体结构。对它们各自结合模式的量子化学计算确定了S1'和S2亚位点中的关键热点相互作用。最有效的抑制剂通过一个α-羟基磺酸酰胺部分靶向S1'亚位点,并表现出良好的功能特性,包括对病原体的生物活性、对SmCB1相对于人组织蛋白酶B的选择性以及合理的代谢稳定性。我们的结果为合理设计下一代SmCB1抑制剂作为治疗血吸虫病的潜在药物提供了结构见解。